secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001493152-25-019370
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 3.02, 8.01, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred
--------------------------------------------------------------------------------

- Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.
- Earnout replaces prior transfer pricing model: 12% of U.S. net sales ≤$65M, 15% if >$65M.
- Closed second tranche of Series C Preferred Stock, raising $2.5M gross; total offering now $11M.
- Believes stockholders' equity now exceeds $5M, regaining compliance with Nasdaq minimum equity requirement.
- Proceeds from preferred stock to fund acquisition and transfer costs and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225019370/0001493152-25-019370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225019370/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer